Exacis Biotherapeutics Presents Data on its Stealth mRNA-Engineered NK-cell Platform at American Society of Gene & Cell Therapy Annual Meeting

May 25, 2021

Exacis Biotherapeutics Presents Data on its Stealth mRNA-Engineered NK-cell Platform at American Society of Gene & Cell Therapy Annual Meeting

– Exacis produces its iPSC-derived ExaNK™ cells using its proprietary mRNA-based cell reprogramming and gene editing technologies

– ExaNK™ cells include a biallelic MHC Class I knockout designed to allow the cells to evade host immune surveillance and enhance persistence in vivo

CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ — Exacis Biotherapeutics Inc., a development-stage immuno-oncology company working to democratize access to the most advanced and effective cancer treatments, revealed key data related to its engineered iPSC-derived NK-cell platform at the American Society of Gene & Cell Therapy 24th Annual Meeting. These data include the successful generation of functional NK cells from iPSCs engineered to contain a biallelic knockout of a key MHC class I gene. Exacis’ cell engineering strategy is designed to allow its ExaNK™ cells to evade surveillance by the patient’s immune system, thus rendering the cells rejection resistant, or “stealth”, to enable increased persistence in patients without genotoxic pre-conditioning.